| Literature DB >> 30519581 |
Pengbo Luo1, Jinjie Lou2, Shengwu Yang2.
Abstract
INTRODUCTION: Internal fixation with volar locking plate (VLP) was widely adopted as a first-line choice in treatment of distal radius fracture (DRF).Entities:
Mesh:
Substances:
Year: 2018 PMID: 30519581 PMCID: PMC6241235 DOI: 10.1155/2018/5786089
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Basic characteristics of 315 study participants by treatment group.
| Celecoxib | Transdermal buprenorphine | Codeine/ |
| |
|---|---|---|---|---|
| Mean (SD) age (years) | 55.7 (15.4) | 54.6 (16.1) | 54.9 (17.2) | 0.82 |
| Sex | ||||
| Male | 34 (23) | 21 (24) | 19 (25) | 0.95 |
| Female | 115 (77) | 68 (76) | 58 (75) | |
| Side of injury | ||||
| Left | 78 (52) | 49 (55) | 39 (51) | 0.85 |
| Right | 71 (48) | 40 (45) | 38 (49) | |
| Handedness of patient | ||||
| Left | 22 (15) | 12 (13) | 13 (17) | 0.83 |
| Right | 127 (85) | 77 (87) | 64 (83) | |
| Fracture classification | ||||
| A1, A2, A3 | 0, 47, 50 (65) | 0, 28, 28 (63) | 0, 25, 26 (66) | 0.99 |
| B1, B2, B3 | 2, 3, 2 (5) | 2, 1, 1 (4) | 1, 1, 1 (4) | |
| C1, C2, C3 | 18, 20, 7 (30) | 13, 11, 5 (33) | 10, 9, 4 (30) | |
| Long-term alcohol consumption | 23 (15) | 13 (15) | 16 (21) | 0.50 |
| Smoker | 25 (17) | 19 (21) | 13 (17) | 0.64 |
Figures are numbers (percentage) unless stated otherwise∗.
VAS scores (mm) measured every week during rehabilitation program.
| Celecoxib | Transdermal buprenorphine | Codeine/ |
| |
|---|---|---|---|---|
| Week 1 | ||||
| VAS score (rest) | 27 (8) | 26 (8) | 28 (8) | 0.35 |
| VAS score (daily activity) | 31 (10) | 32 (10) | 33 (11) | 0.66 |
| VAS score (rehabilitative exercise) | 67 (22)# | 45 (14) | 42 (12) | < 0.01 |
| Completing the rehabilitation program | 80 (54) | 68 (76) | 57 (74) | < 0.01 |
| Week 2 | ||||
| VAS score (rest) | 24 (7) | 22 (7) | 23 (6) | 0.29 |
| VAS score (daily activity) | 26 (9) | 25 (8) | 24 (10) | 0.34 |
| VAS score (rehabilitative exercise) | 41 (17)# | 30 (11) | 32 (10) | < 0.01 |
| Completing the rehabilitation program | 110 (74) | 76 (85) | 66 (86) | 0.03 |
| Week 3 | ||||
| VAS score (rest) | 19 (6) | 18 (5) | 18 (6) | 0.11 |
| VAS score (daily activity) | 22 (7) | 20 (7) | 21 (7) | 0.10 |
| VAS score (rehabilitative exercise) | 26 (8) | 24 (8) | 24 (8) | 0.16 |
| Completing the rehabilitation program | 135 (91) | 80 (90) | 68 (88) | 0.86 |
| Week 4 | ||||
| VAS score (rest) | 15 (5) | 16 (5) | 16 (5) | 0.37 |
| VAS score (daily activity) | 16 (6) | 15 (5) | 17 (8) | 0.39 |
| VAS score (rehabilitative exercise) | 17 (8) | 19 (9) | 18 (6) | 0.20 |
| Completing the rehabilitation program | 141 (95) | 82 (92) | 72 (94) | 0.75 |
| Week 5 | ||||
| VAS score (rest) | 12 (4) | 12 (4) | 12 (4) | 0.82 |
| VAS score (daily activity) | 12 (5) | 13 (6) | 11 (5) | 0.39 |
| VAS score (rehabilitative exercise) | 14 (5) | 14 (5) | 14 (7) | 0.85 |
| Completing the rehabilitation program | 144 (97) | 86 (97) | 73 (95) | 0.77 |
| Week 6 | ||||
| VAS score (rest) | 6 (4) | 7 (4) | 7 (4) | 0.11 |
| VAS score (daily activity) | 8 (4) | 8 (4) | 8 (4) | 0.35 |
| VAS score (rehabilitative exercise) | 8 (3) | 7 (3) | 8 (3) | 0.04 |
| Completing the rehabilitation program | 142 (95) | 84 (94) | 74 (96) | 0.87 |
Pain medication was given only in Week 1 and 2. Figures are Mean (SD) for VAS score and otherwise number (percentage).
∗P < 0.05 versus celecoxib group; # P < 0.05 versus transdermal buprenorphine group. P value was calculated using Student's t test.
Figure 1PRWE and DASH scores at one, three, and six months postoperatively.
Functional outcomes at one, three, and six months postoperatively.
| Celecoxib | Transdermal buprenorphine | Codeine/ |
| |
|---|---|---|---|---|
| One month | ||||
| PRWE | 40 (13)# | 26 (10) | 24 (11) | < 0.01 |
| PRWE (pain subscale) | 14 (6) | 13 (5) | 12 (6) | 0.63 |
| DASH | 42 (16)# | 30 (14) | 32 (12) | < 0.01 |
| Grip strength (%) | 45 (13) | 46 (21) | 47 (20) | 0.78 |
| Extension (%) | 43 (16) # | 61 (18) | 60 (15) | < 0.01 |
| Flexion (%) | 60 (21) # | 71 (22) | 71 (18) | < 0.01 |
| Pronation (%) | 80 (21) | 79 (24) | 83 (20) | 0.55 |
| Supination (%) | 54 (16) # | 60 (22) | 60 (28) | 0.03 |
| Ulnar abduction (%) | 45 (18) # | 60 (15) | 61 (19) | < 0.01 |
| Radial abduction (%) | 50 (23) # | 57 (21) | 59 (26) | 0.01 |
| Three months | ||||
| PRWE | 18 (8) # | 16 (6) | 16 (7) | 0.04 |
| PRWE (pain subscale) | 5 (2) | 6 (3) | 5 (3) | 0.67 |
| DASH | 25 (9) # | 21 (7) | 20 (7) | < 0.01 |
| Grip strength (%) | 91 (9) | 91 (7) | 90 (9) | 0.79 |
| Extension (%) | 73 (17) # | 78 (20) | 80 (26) | 0.02 |
| Flexion (%) | 78 (30) | 84 (22) | 87 (23) | 0.04 |
| Pronation (%) | 90 (10) | 93 (16) | 91 (12) | 0.21 |
| Supination (%) | 60 (21) # | 68 (27) | 67 (28) | 0.02 |
| Ulnar abduction (%) | 65 (18) # | 78 (21) | 76 (25) | < 0.01 |
| Radial abduction (%) | 68 (19) # | 75 (23) | 75 (26) | 0.03 |
| Six Months | ||||
| PRWE | 5( 3) | 6 (3) | 5 (3) | 0.28 |
| PRWE (pain subscale) | 3 (2) | 3 (2) | 2 (1) | 0.81 |
| DASH | 8 (3) | 8 (5) | 8 (3) | 0.95 |
| Grip strength (%) | 90 (10) | 89 (9) | 91 (6) | 0.46 |
| Extension (%) | 92 (12) | 92 (10) | 91 (8) | 0.81 |
| Flexion (%) | 93 (11) | 96 (10) | 93 (9) | 0.12 |
| Pronation (%) | 93 (6) | 93 (8) | 92 (10) | 0.76 |
| Supination (%) | 90 (11) | 90 (13) | 88 (15) | 0.26 |
| Ulnar abduction (%) | 86 (15) # | 91 (12) | 90 (13) | 0.01 |
| Radial abduction (%) | 88 (17) # | 93 (15) | 93 (15) | 0.04 |
Figures are mean (SD).
∗P < 0.05 versus celecoxib group; # P < 0.05 versus transdermal buprenorphine group. P value was calculated using Student's t-test.